Matteo Della Porta: The final analysis of the COMMANDS trial comparing Luspatercept vs Epoetin alfa

Matteo Della Porta, Professor of Hematology at Humanitas University and Head of CALR (Center for Accelerating Leukemia/Lymphoma Research), shared a post on LinkedIn:

”Just published in Lancet Haematology the final analysis of the COMMANDS trial comparing Luspatercept vs. Epoetin alfa as first line treatment of patients with lower-risk Myelodysplastic Syndromes (MDS) and transfusion-dependent anemia.

Luspatercept represents a new standard of care for patients with transfusion-dependent, lower-risk MDS. Significantly more patients had red blood cell transfusion independence and hematological improvement with Luspatercept than with Epoetin alfa, with benefits observed across patient subgroups.”

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

Authors: Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Richard Pilot, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Thomas Prebet, Yinzhi Lai, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Uwe Platzbecker.

Source: Matteo Della Porta/LinkedIn